glp-1 nobel prize agonists have transformed life for many people with type 2 diabetes and obesity. The 2025 Breakthrough honors Daniel Drucker, Joel Habener, Jens Juul Holst, Lotte Bjerre Knudsen and Svetlana Mojsov A future Nobel Prize? Looking

The same mechanism as semaglutide

Gastroenterol Clin North Am

Under the condition of exogenous NPY overexpression, bone formation and bone microarchitecture were disrupted, pyroptosis-related molecules such as NOD-like receptor protein 3 (NLRP3) and Caspase-1 in subchondral cancellous bone were upregulated, and the levels of colonic inflammatory indicators like IL-1, IL-18, and serum LPS were elevated as well

If youre starting a GLP-1, heres how to recognize (and hopefully minimize) the most common side effects

The pattern is consistent : your Medicaid program covers these medications for diabetes but not obesity in most states

DELICIOUS ANTIOXIDANT BOOST: Experience wellness that actually tastes good